Recruiting × Interventional × Hematologic Neoplasms × Clear all CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Phase 1/2 Recruiting
152 enrolled
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
Phase 3 Recruiting
400 enrolled
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
Phase 1 Recruiting
30 enrolled
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
Phase 2 Recruiting
55 enrolled
PRAGMATIC
Phase 2 Recruiting
104 enrolled
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Phase 1 Recruiting
86 enrolled
QUATRO-APL
Phase 3 Recruiting
150 enrolled
oncOPAL
Phase NA Recruiting
150 enrolled
Mind-body Medicine for Patients With Malignant Hematological Diseases
Phase NA Recruiting
94 enrolled
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Phase 2 Recruiting
30 enrolled
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Phase 1 Recruiting
117 enrolled
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 2 Recruiting
80 enrolled
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
Phase 1/2 Recruiting
70 enrolled
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
171 enrolled
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 Recruiting
280 enrolled
MK-3475-587
Phase 3 Recruiting
3,500 enrolled
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Phase 1 Recruiting
300 enrolled
MonumenTAL-1
Phase 2 Recruiting
510 enrolled 2 FDA
MK-1026-003
Phase 2 Recruiting
490 enrolled
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
Phase 1 Recruiting
50 enrolled
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Phase 2 Recruiting
46 enrolled
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Phase 1 Recruiting
60 enrolled
ADAPT-HEM
Phase 1/2 Recruiting
96 enrolled
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Phase 1/2 Recruiting
320 enrolled
Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)
Phase NA Recruiting
200 enrolled
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Phase 3 Recruiting
1,300 enrolled
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Phase 1/2 Recruiting
265 enrolled
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 Recruiting
70 enrolled
Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT
Phase 3 Recruiting
218 enrolled
GVHD-PTCy
Phase 2 Recruiting
41 enrolled
IVIG for Infection Prevention After CAR-T-Cell Therapy
Phase 2 Recruiting
150 enrolled
ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
Phase NA Recruiting
160 enrolled
(HEM-FLU)
Phase 3 Recruiting
60 enrolled
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Phase 1/2 Recruiting
260 enrolled
NiCE
Phase NA Recruiting
120 enrolled
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Phase 1/2 Recruiting
420 enrolled
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Phase 1 Recruiting
42 enrolled
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Phase 1/2 Recruiting
160 enrolled
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Phase 1 Recruiting
420 enrolled
Early Detection of Complications During Immunotherapy for Haematological Malignancy
Phase NA Recruiting
100 enrolled
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Phase 2 Recruiting
78 enrolled
CARE-T
Phase NA Recruiting
100 enrolled
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
Phase NA Recruiting
256 enrolled
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
Phase 2 Recruiting
312 enrolled
Discontinuation Study
Phase NA Recruiting
70 enrolled
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Phase 1 Recruiting
20 enrolled
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
Phase 1 Recruiting
20 enrolled
HORIZONS
Phase NA Recruiting
350 enrolled
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Phase 2 Recruiting
15 enrolled
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Phase 3 Recruiting
105 enrolled